Trimel Pharmaceuticals Corporation
TSX : TRL

Trimel Pharmaceuticals Corporation

March 01, 2012 07:30 ET

Trimel Pharmaceuticals Corporation to Report Financial Results for 2011 and Host a Conference Call to Update Investors

TORONTO, ONTARIO--(Marketwire - March 1, 2012) - Trimel Pharmaceuticals Corporation (TSX:TRL) will report its financial results for the 3 month and 12 month periods ended December 31, 2011 on Thursday, March 8th after the market closes.

Management of the Company will host a conference call to discuss its 2011 financial results and update investors on the status of its business on Friday March 9th, 2012, at 8:30 a.m. Eastern Time. Presenting from Trimel will be Bruce Brydon, Chairman of the Board and Chief Executive Officer, Tom Rossi, President and Kenneth Howling, Chief Financial Officer.

To access the call live, please dial 416-340-2219 (Toronto), 1-866-226-1798 (Canada and U.S.), and 00-800-9559-6849 (International). Listeners are encouraged to dial in 10 minutes before the call begins to avoid delays.

A replay of the conference call will be available until 7:00 p.m. Eastern Time on Friday March 16th by dialing 905-694-9451 (Toronto), 1-800-408-3053 (Canada and U.S.) or 00-800-3366-3052 (International), using access code: 7046128#.

For further information regarding Trimel Pharmaceuticals Corporation, please contact either Bruce Brydon at 416-679-0711 or Kenneth Howling at 416-679-0536 or via email at ir@trimelpharmaceuticals.com.

About Trimel

Trimel Pharmaceuticals Corporation (TSX:TRL) - Developing medications for Female Sexual Health and conditions related to Aging, and Well Being. Trimel is developing multiple product opportunities, including CompleoTRT, a bio-adhesive intranasal Testosterone gel currently in a Phase III clinical study for the treatment of male hypogonadism, a condition commonly referred to as "Low T". For more information, please visit www.trimelpharmaceuticals.com.

Contact Information